Metrorrhagia
Conditions
Keywords
Dysfunctional Uterine Bleeding
Brief summary
The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
Detailed description
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Interventions
2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
DRUGPlacebo
Matching placebo to be taken orally daily.
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women 18 years or older * With diagnosis of dysfunctional uterine bleeding without organic pathology * And with at least one of the following symptoms: prolonged, frequent, or excessive bleeding
Exclusion criteria
* The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study. * Women with history of endometrial ablation or dilatation or curettage within 2 months prior to study start will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms | during a time period of 90 days under treatment | Up to 8 criteria had to be met for complete response during 90-day period. No bleeding episodes (BE) \>7 days, no \>4 BE, no BE with MBL \>=80 mL, no \>1 BE increase from baseline, no increase from baseline in an individual participant's total number of bleeding days and total number of bleeding days not \>24 days. Additionally, for participants included with prolonged bleeding: decrease between maximum duration during run-in and efficacy \>=2 days excessive bleeding: MBL associated with each episode decreased by \>=50% from average of qualifying episodes during run-in. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants Cured From Frequent Bleeding | during a time period of 90 days under treatment | Frequent bleeding was defined as greater than 5 bleeding episodes, with a minimum of 20 bleeding days overall in a 90-day period. Participants were considered cured if they had no more than 4 bleeding episodes and the total number of bleeding days did not exceed 24 days and there was no increase in the total number of bleeding days in the efficacy phase as compared to the run-in phase. |
| Proportion of Participants Cured From Excessive Bleeding | during a time period of 90 days under treatment | Excessive bleeding was defined as 2 or more bleeding episodes each with blood loss volume of 80 mL or more in a 90-day period. Participants were considered cured if (1) the blood loss volume associated with each episode was less than 80 mL and (2) the blood loss volume associated with each bleeding episode represented a decrease of at least 50% from the average of the qualifying bleeding episodes, where the qualifying bleeding episodes were those with a blood loss volume ≥ 80 mL (per episode) that occurred during the run-in phase. |
| Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84 | from baseline up to treatment day 84 | The investigators assessed the participants' change in DUB symptoms at day 84 (visit 7) compared with admission to the study according to a scale of 1 (very much improved) to 7 (very much worse), using the following information: central laboratory data, physical examination, e-diary data, and participant interview. Improvement was defined as being classified as a score of 3 or less. |
| Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196 | from baseline up to treatment day 196 | The investigators assessed the participants' change in DUB symptoms at day 196 (visit 11) compared with admission to the study according to a scale of 1 (very much improved) to 7 (very much worse), using the following information: central laboratory data, physical examination, e-diary data, and participant interview. Improvement was defined as being classified as a score of 3 or less. |
| Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84 | from baseline up to treatment day 84 | Participants assessed their overall improvement at day 84 (visit 7) compared with their condition at admission to the study on a scale of 1 (very much improved) to 7 (very much worse). Improvement was defined as being classified as a score of 3 or less. |
| Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196 | from baseline up to treatment day 196 | Participants assessed their overall improvement at day 196 (visit 11) compared with their condition at admission to the study on a scale of 1 (very much improved) to 7 (very much worse). Improvement was defined as being classified as a score of 3 or less. |
| Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment | Baseline and reference period of 90 days under treatment | Menstrual blood loss was determined using the alkaline hematin method for the 90 days before treatment (baseline) and for 90 days under treatment. A negative value indicates a reduction in blood loss after treatment. |
| Menstrual Blood Loss Volume for All Participants at Cycle 1 | 28 days | Menstrual blood loss volume was determined using the alkaline hematin method after participants were on treatment for one cycle |
| Menstrual Blood Loss Volume for All Participants at Cycle 3 | 28 days | Menstrual blood loss volume was determined using the alkaline hematin method after participants were on treatment for 3 cycles |
| Menstrual Blood Loss Volume for All Participants at Cycle 7 | 28 days | Menstrual blood loss volume was determined using the alkaline hematin methods after participants were on treatment for 7 cycles |
| Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment | baseline and reference period of 90 days under treatment | The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined for the 90 days before treatment (ie, run-in phase) and for the 90 days under treatment. A negative value indicates a reduction in blood loss while under treatment compared to before treatment. |
| Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1 | 28 days | The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for one cycle. |
| Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3 | 28 days | The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for 3 cycles. |
| Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7 | 28 days | The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for 7 cycles. |
| Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment | baseline and reference period of 90 days under treatment | The number of bleeding days was determine for the 90 days before treatment (baseline) and for 90 days while under treatment. A negative value indicates a reduction in the number of bleeding days while under treatment compared to baseline. |
| Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment | baseline and reference period of 90 days under treatment | A bleeding episode was one that lasted for at least 2 days, and where the bleeding days were separated by no more than 1 bleeding-free day. An episode stopped with 2 consecutive bleeding-free days. The number of episodes was determined for the 90 days before treatment and for the 90 days under treatment. A negative values indicates a reduction from baseline in the number of episodes while under treatment. |
| Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment | baseline and reference period of 90 days under treatment | The number of total sanitary protection items used during the 90-day run-in phase before treatment (baseline) and the number of total sanitary protection items used during the 90 days while under treatment was determined. A negative value indicates a reduction in the number of sanitary protection items used while under treatment compared to the number used before treatment. |
| Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84 | baseline and treatment day 84 | The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum was 132. The higher the score, the better the well being of the participant. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196 | treatment day 196 | Participants were asked how many days and hours were missed from work during the past 12 weeks because of problems associated with DUB, not including the time missed to participate in this study. |
| Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196 | baseline and treatment day 196 | The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum was 132. The higher the score, the better the well being of the participant. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively. |
| Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84 | baseline and treatment day 84 | The MFSQ was designed to measure aspects of female sexuality and asked about the participants' sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum possible values are 19 and 133. |
| Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196 | baseline and treatment day 196 | The MFSQ was designed to measure aspects of female sexuality and asked about the participants' sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum possible values are 19 and 133. |
| Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84 | baseline and treatment day 84 | The Health State Classification of the EQ-5D comprised 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Participants were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a valuation score of .594. The change from the baseline score at day 84 is presented. |
| Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196 | baseline and treatment day 196 | The Health State Classification of the EQ-5D comprised 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Participants were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a valuation score of .594. The change from the baseline score at day 196 is presented. |
| Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84 | baseline and treatment day 84 | The visual analogue scale (ie, thermometer) had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Participants rated their current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the thermometer scale. The change from baseline at day 84 is presented. |
| Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196 | baseline and treatment day 196 | The visual analogue scale (ie, thermometer) had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Participants rated their current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the thermometer scale. The change from baseline at day 196 is presented. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84 | treatment day 84 | Participants were asked if there was any change in her employment status in the last 12 weeks. The proportion of participants with a change is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84 | treatment day 84 | Participants were asked how many days and hours they missed from work during the past 12 weeks because of problems associated with DUB, not including the time missed to participate in this study. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84 | treatment day 84 | Participants were asked to rate on a scale of 0 to 10, how much their DUB affected productivity while working during the past 12 weeks, where 0 represented that DUB had no effect on work and 10 represented that DUB completely prevented her from working. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84 | treatment day 84 | Participants were asked to rate on a scale of 0 to 10 how much DUB affected their ability to do their regular daily activities, other than work at a job, during the past 12 weeks where 0 represented that DUB had no effect on daily activities and 10 represented that DUB completely prevented her from doing daily activities. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196 | treatment day 196 | Participants were asked to rate on a scale of 0 to 10, how much DUB affected their productivity while working during the past 12 weeks, where 0 represented that DUB had no effect on work and 10 represented that DUB completely prevented her from working. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196 | treatment day 196 | Participants were asked to rate on a scale of 0 to 10 how much DUB affected their ability to do regular daily activities, other than work at a job, during the past 12 weeks where 0 represented that DUB had no effect on daily activities and 10 represented that DUB completely prevented her from doing her daily activities. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84 | treatment day 84 | Participants were asked if they had any unscheduled outpatient visits to a hospital because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84 | treatment day 84 | Participants were asked if they had any unscheduled visits to a physician (non-hospital medical care) because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84 | treatment day 84 | Participants were asked if they had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of DUB during the past 12 weeks. The proportion of participants with such procedures is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84 | treatment day 84 | Participants were asked if they had received ambulatory services (eg, home help, child care) because of DUB during the past 12 weeks. The proportion of participants who received such services is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84 | treatment day 84 | Participants were asked to specify if they had out-of-pocket expenses because of DUB during the past 12 weeks, including over-the-counter medication (the name of the medication, the number of packages, and the cost per package), co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with such expenses is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84 | treatment day 84 | Participants were asked if they had any medical treatment (eg, prescribed medication, other treatment) because of DUB during the past 12 weeks. The proportion of participants with such treatment is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196 | treatment day 196 | Participants were asked if there was any change in employment status in the last 12 weeks. The proportion of participants with a change is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196 | treatment day 196 | Participants were asked if they had any unscheduled outpatient visits to a hospital because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196 | treatment day 196 | Participants were asked if they had any unscheduled visits to a physician (non-hospital medical care) because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196 | treatment day 196 | Participants were asked if they had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of DUB during the past 12 weeks. The proportion of participants with such procedures is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196 | treatment day 196 | Participants were asked if they had received ambulatory services (eg, home help, child care) because of DUB during the past 12 weeks. The proportion of participants who had received such services is displayed. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196 | treatment day 196 | Participants were asked to specify out-of-pocket expenses because of DUB during the past 12 weeks, including over-the-counter medication, co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with such expenses is displayed. |
| Proportion of Participants Cured From Prolonged Bleeding | during a time period of 90 days under treatment | Prolonged bleeding was defined as 2 or more bleeding episodes, each lasting 8 or more days in a 90-day period. Participants were considered cured if they had no bleeding episodes lasting more than 7 days and the decrease between the maximum duration during the run-in phase and the maximum duration during the efficacy phase was at least 2 days. |
| Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196 | baseline and treatment day 196 | Hematocrit was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hematocrit from baseline at treatment day 196. |
| Change From Baseline in Serum Ferritin Concentration at Treatment Day 84 | baseline and treatment day 84 | Serum ferritin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in serum ferritin from baseline at treatment day 84. |
| Change From Baseline in Serum Ferritin Concentration at Treatment Day 196 | baseline and treatment day 196 | Serum ferritin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in serum ferritin from baseline at treatment day 196. |
| Change From Baseline in Hemoglobin Concentration at Treatment Day 84 | baseline and treatment day 84 | Hemoglobin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 84. |
| Change From Baseline in Hemoglobin Concentration at Treatment Day 196 | baseline and treatment day 196 | Hemoglobin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 196. |
| Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196 | treatment day 196 | Participants were asked if they had any medical treatment (eg, prescribed medication, other treatment) because of DUB during the past 12 weeks. The proportion of participants with such treatment is displayed. |
Countries
Canada, United States
Participant flow
Recruitment details
The date of first participant, first visit was 14 Dec 2005. The date of last participant, last visit was 21 May 2008.
Pre-assignment details
A total of 1077 participants were screened for inclusion into the study; 887 participants failed screening. The remaining 190 participants were randomized; 120 participants were randomized to the estradiol valerate/dienogest group and 70 participants to the placebo group.
Participants by arm
| Arm | Count |
|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo | 120 |
| Placebo Matching placebo to be taken orally daily | 70 |
| Total | 190 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 12 | 4 |
| Overall Study | Lack of Efficacy | 2 | 0 |
| Overall Study | Lost to Follow-up | 2 | 3 |
| Overall Study | missing | 3 | 5 |
| Overall Study | Noncompliant - sanitary pads collection | 0 | 1 |
| Overall Study | Participant moved out of state | 1 | 0 |
| Overall Study | Participant stopped study drug | 1 | 0 |
| Overall Study | Pregnancy | 1 | 1 |
| Overall Study | Protocol Violation | 2 | 0 |
| Overall Study | Withdrawal by Subject | 11 | 5 |
Baseline characteristics
| Characteristic | Placebo | Total | Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) |
|---|---|---|---|
| Age Continuous | 37.0 Years STANDARD_DEVIATION 6.7 | 36.9 Years STANDARD_DEVIATION 7.2 | 36.9 Years STANDARD_DEVIATION 7.5 |
| Body Mass Index (BMI) | 25.8 kg/m^2 STANDARD_DEVIATION 3.6 | 26.1 kg/m^2 STANDARD_DEVIATION 3.6 | 26.3 kg/m^2 STANDARD_DEVIATION 3.6 |
| excessive bleeding | 60 participants | 151 participants | 91 participants |
| frequent and excessive bleeding | 0 participants | 1 participants | 1 participants |
| frequent bleeding | 2 participants | 6 participants | 4 participants |
| prolonged and excessive bleeding | 9 participants | 18 participants | 9 participants |
| prolonged and frequent bleeding | 2 participants | 5 participants | 3 participants |
| prolonged bleeding | 12 participants | 38 participants | 26 participants |
| prolonged, frequent and excessive bleeding | 0 participants | 0 participants | 0 participants |
| Sex: Female, Male Female | 70 Participants | 190 Participants | 120 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 46 / 119 | 21 / 66 |
| serious Total, serious adverse events | 1 / 119 | 2 / 66 |
Outcome results
Primary
Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms
Up to 8 criteria had to be met for complete response during 90-day period. No bleeding episodes (BE) \>7 days, no \>4 BE, no BE with MBL \>=80 mL, no \>1 BE increase from baseline, no increase from baseline in an individual participant's total number of bleeding days and total number of bleeding days not \>24 days. Additionally, for participants included with prolonged bleeding: decrease between maximum duration during run-in and efficacy \>=2 days excessive bleeding: MBL associated with each episode decreased by \>=50% from average of qualifying episodes during run-in.
Time frame: during a time period of 90 days under treatment
Population: The intent-to-treat (ITT) group consisted of all randomized participants.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms | 0.292 Proportion of participants |
| Placebo | Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms | 0.029 Proportion of participants |
p-value: <0.0001inverting 2 one-sided tests
Secondary
Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment
Menstrual blood loss was determined using the alkaline hematin method for the 90 days before treatment (baseline) and for 90 days under treatment. A negative value indicates a reduction in blood loss after treatment.
Time frame: Baseline and reference period of 90 days under treatment
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment | -353.1 mL | Standard Deviation 309.4 |
| Placebo | Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment | -130.4 mL | Standard Deviation 338.3 |
Secondary
Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment
The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined for the 90 days before treatment (ie, run-in phase) and for the 90 days under treatment. A negative value indicates a reduction in blood loss while under treatment compared to before treatment.
Time frame: baseline and reference period of 90 days under treatment
Population: ITT, participants with excessive bleeding at baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment | -411.9 mL | Standard Deviation 308.5 |
| Placebo | Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment | -152.3 mL | Standard Deviation 343.2 |
Secondary
Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196
The Health State Classification of the EQ-5D comprised 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Participants were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a valuation score of .594. The change from the baseline score at day 196 is presented.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196 | 0.0052 Scores on a scale | Standard Deviation 0.1504 |
| Placebo | Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 196 | 0.0154 Scores on a scale | Standard Deviation 0.1611 |
Secondary
Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84
The Health State Classification of the EQ-5D comprised 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Participants were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a valuation score of .594. The change from the baseline score at day 84 is presented.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84 | -0.0035 scores on a scale | Standard Deviation 0.2145 |
| Placebo | Change From Baseline in EuroQoL (Quality of Life) 5 Dimensional Health Questionnaire (EQ-5D) Scores at Treatment Day 84 | -0.0024 scores on a scale | Standard Deviation 0.1507 |
Secondary
Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196
Hematocrit was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hematocrit from baseline at treatment day 196.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196 | 1.30 Percentage of blood volume | Standard Deviation 2.98 |
| Placebo | Change From Baseline in Hematocrit (Hct) Concentrations at Treatment Day 196 | 0.09 Percentage of blood volume | Standard Deviation 3.04 |
Secondary
Change From Baseline in Hemoglobin Concentration at Treatment Day 196
Hemoglobin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 196.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Hemoglobin Concentration at Treatment Day 196 | 0.57 g/dL | Standard Deviation 1.02 |
| Placebo | Change From Baseline in Hemoglobin Concentration at Treatment Day 196 | 0.20 g/dL | Standard Deviation 1.03 |
Secondary
Change From Baseline in Hemoglobin Concentration at Treatment Day 84
Hemoglobin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 84.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Hemoglobin Concentration at Treatment Day 84 | 0.22 g/dL | Standard Deviation 0.83 |
| Placebo | Change From Baseline in Hemoglobin Concentration at Treatment Day 84 | 0.17 g/dL | Standard Deviation 0.62 |
Secondary
Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196
The MFSQ was designed to measure aspects of female sexuality and asked about the participants' sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum possible values are 19 and 133.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196 | -2.0 Scores on a scale | Standard Deviation 15.9 |
| Placebo | Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 196 | -0.8 Scores on a scale | Standard Deviation 9.1 |
Secondary
Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84
The MFSQ was designed to measure aspects of female sexuality and asked about the participants' sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum possible values are 19 and 133.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84 | -3.5 Scores on a scale | Standard Deviation 12 |
| Placebo | Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Scores at Treatment Day 84 | 0.8 Scores on a scale | Standard Deviation 8.4 |
Secondary
Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment
The number of bleeding days was determine for the 90 days before treatment (baseline) and for 90 days while under treatment. A negative value indicates a reduction in the number of bleeding days while under treatment compared to baseline.
Time frame: baseline and reference period of 90 days under treatment
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment | -5.2 bleeding days | Standard Deviation 11.4 |
| Placebo | Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment | -2.0 bleeding days | Standard Deviation 6.2 |
Secondary
Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment
A bleeding episode was one that lasted for at least 2 days, and where the bleeding days were separated by no more than 1 bleeding-free day. An episode stopped with 2 consecutive bleeding-free days. The number of episodes was determined for the 90 days before treatment and for the 90 days under treatment. A negative values indicates a reduction from baseline in the number of episodes while under treatment.
Time frame: baseline and reference period of 90 days under treatment
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment | -0.5 bleeding episodes | Standard Deviation 1.5 |
| Placebo | Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment | -0.3 bleeding episodes | Standard Deviation 0.9 |
Secondary
Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment
The number of total sanitary protection items used during the 90-day run-in phase before treatment (baseline) and the number of total sanitary protection items used during the 90 days while under treatment was determined. A negative value indicates a reduction in the number of sanitary protection items used while under treatment compared to the number used before treatment.
Time frame: baseline and reference period of 90 days under treatment
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment | -43.6 Sanitary protection products | Standard Deviation 40.9 |
| Placebo | Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment | -21.2 Sanitary protection products | Standard Deviation 43.2 |
Secondary
Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196
The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum was 132. The higher the score, the better the well being of the participant. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196 | 0.7 Scores on a scale | Standard Deviation 14.6 |
| Placebo | Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 196 | 1.0 Scores on a scale | Standard Deviation 10.1 |
Secondary
Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84
The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum was 132. The higher the score, the better the well being of the participant. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84 | -1.0 Scores on a scale | Standard Deviation 13.4 |
| Placebo | Change From Baseline in Psychological General Well-Being Index (PGWBI) Scores at Treatment Day 84 | -0.7 Scores on a scale | Standard Deviation 10.1 |
Secondary
Change From Baseline in Serum Ferritin Concentration at Treatment Day 196
Serum ferritin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in serum ferritin from baseline at treatment day 196.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Serum Ferritin Concentration at Treatment Day 196 | 5.3 ng/mL | Standard Deviation 37.8 |
| Placebo | Change From Baseline in Serum Ferritin Concentration at Treatment Day 196 | 2.0 ng/mL | Standard Deviation 11.9 |
Secondary
Change From Baseline in Serum Ferritin Concentration at Treatment Day 84
Serum ferritin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in serum ferritin from baseline at treatment day 84.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Serum Ferritin Concentration at Treatment Day 84 | 0.2 ng/mL | Standard Deviation 35.6 |
| Placebo | Change From Baseline in Serum Ferritin Concentration at Treatment Day 84 | -1.5 ng/mL | Standard Deviation 12.2 |
Secondary
Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196
The visual analogue scale (ie, thermometer) had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Participants rated their current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the thermometer scale. The change from baseline at day 196 is presented.
Time frame: baseline and treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196 | -0.07 Scores on a scale | Standard Deviation 12.86 |
| Placebo | Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196 | -0.51 Scores on a scale | Standard Deviation 12.9 |
Secondary
Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84
The visual analogue scale (ie, thermometer) had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Participants rated their current health state by drawing a line from the box marked 'your own health state today' to the appropriate point on the thermometer scale. The change from baseline at day 84 is presented.
Time frame: baseline and treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84 | -2.07 Scores on a scale | Standard Deviation 11.74 |
| Placebo | Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84 | -0.26 Scores on a scale | Standard Deviation 10.38 |
Secondary
Menstrual Blood Loss Volume for All Participants at Cycle 1
Menstrual blood loss volume was determined using the alkaline hematin method after participants were on treatment for one cycle
Time frame: 28 days
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for All Participants at Cycle 1 | 136.5 mL | Standard Deviation 141.3 |
| Placebo | Menstrual Blood Loss Volume for All Participants at Cycle 1 | 146.9 mL | Standard Deviation 133.9 |
Secondary
Menstrual Blood Loss Volume for All Participants at Cycle 3
Menstrual blood loss volume was determined using the alkaline hematin method after participants were on treatment for 3 cycles
Time frame: 28 days
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for All Participants at Cycle 3 | 59.9 mL | Standard Deviation 91.5 |
| Placebo | Menstrual Blood Loss Volume for All Participants at Cycle 3 | 139.6 mL | Standard Deviation 92.2 |
Secondary
Menstrual Blood Loss Volume for All Participants at Cycle 7
Menstrual blood loss volume was determined using the alkaline hematin methods after participants were on treatment for 7 cycles
Time frame: 28 days
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for All Participants at Cycle 7 | 41.3 mL | Standard Deviation 54.2 |
| Placebo | Menstrual Blood Loss Volume for All Participants at Cycle 7 | 113.3 mL | Standard Deviation 76.6 |
Secondary
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1
The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for one cycle.
Time frame: 28 days
Population: ITT, participants with excessive bleeding at baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1 | 206.1 mL | Standard Deviation 179.8 |
| Placebo | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1 | 194.7 mL | Standard Deviation 132.2 |
Secondary
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3
The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for 3 cycles.
Time frame: 28 days
Population: ITT, participants with excessive bleeding at baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3 | 67.1 mL | Standard Deviation 96.2 |
| Placebo | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3 | 147.4 mL | Standard Deviation 93.4 |
Secondary
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7
The blood loss volume for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 mL or more during the run-in phase) was determined using the alkaline hematin method after participants were on treatment for 7 cycles.
Time frame: 28 days
Population: ITT, participants with excessive bleeding at baseline
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7 | 47.5 mL | Standard Deviation 58.5 |
| Placebo | Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7 | 116.9 mL | Standard Deviation 77.5 |
Secondary
Proportion of Participants Cured From Excessive Bleeding
Excessive bleeding was defined as 2 or more bleeding episodes each with blood loss volume of 80 mL or more in a 90-day period. Participants were considered cured if (1) the blood loss volume associated with each episode was less than 80 mL and (2) the blood loss volume associated with each bleeding episode represented a decrease of at least 50% from the average of the qualifying bleeding episodes, where the qualifying bleeding episodes were those with a blood loss volume ≥ 80 mL (per episode) that occurred during the run-in phase.
Time frame: during a time period of 90 days under treatment
Population: The ITT population consisted of all randomized participants who enrolled with excessive bleeding.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants Cured From Excessive Bleeding | 0.385 Proportion of participants |
| Placebo | Proportion of Participants Cured From Excessive Bleeding | 0.05 Proportion of participants |
Secondary
Proportion of Participants Cured From Frequent Bleeding
Frequent bleeding was defined as greater than 5 bleeding episodes, with a minimum of 20 bleeding days overall in a 90-day period. Participants were considered cured if they had no more than 4 bleeding episodes and the total number of bleeding days did not exceed 24 days and there was no increase in the total number of bleeding days in the efficacy phase as compared to the run-in phase.
Time frame: during a time period of 90 days under treatment
Population: The ITT population consisted of all randomized participants who enrolled with frequent bleeding.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants Cured From Frequent Bleeding | 0.250 Proportion of participants |
| Placebo | Proportion of Participants Cured From Frequent Bleeding | 0.0 Proportion of participants |
Secondary
Proportion of Participants Cured From Prolonged Bleeding
Prolonged bleeding was defined as 2 or more bleeding episodes, each lasting 8 or more days in a 90-day period. Participants were considered cured if they had no bleeding episodes lasting more than 7 days and the decrease between the maximum duration during the run-in phase and the maximum duration during the efficacy phase was at least 2 days.
Time frame: during a time period of 90 days under treatment
Population: The ITT population consisted of all randomized participants who enrolled with prolonged bleeding.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants Cured From Prolonged Bleeding | 0.154 Proportion of participants |
| Placebo | Proportion of Participants Cured From Prolonged Bleeding | 0.083 Proportion of participants |
Secondary
Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196
The investigators assessed the participants' change in DUB symptoms at day 196 (visit 11) compared with admission to the study according to a scale of 1 (very much improved) to 7 (very much worse), using the following information: central laboratory data, physical examination, e-diary data, and participant interview. Improvement was defined as being classified as a score of 3 or less.
Time frame: from baseline up to treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196 | 0.807 Proportion of participants |
| Placebo | Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196 | 0.419 Proportion of participants |
Secondary
Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84
The investigators assessed the participants' change in DUB symptoms at day 84 (visit 7) compared with admission to the study according to a scale of 1 (very much improved) to 7 (very much worse), using the following information: central laboratory data, physical examination, e-diary data, and participant interview. Improvement was defined as being classified as a score of 3 or less.
Time frame: from baseline up to treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84 | 0.880 Proportion of participants |
| Placebo | Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84 | 0.509 Proportion of participants |
Secondary
Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196
Participants assessed their overall improvement at day 196 (visit 11) compared with their condition at admission to the study on a scale of 1 (very much improved) to 7 (very much worse). Improvement was defined as being classified as a score of 3 or less.
Time frame: from baseline up to treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196 | 0.812 Proportion of participants |
| Placebo | Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 196 | 0.383 Proportion of participants |
Secondary
Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84
Participants assessed their overall improvement at day 84 (visit 7) compared with their condition at admission to the study on a scale of 1 (very much improved) to 7 (very much worse). Improvement was defined as being classified as a score of 3 or less.
Time frame: from baseline up to treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84 | 0.835 Proportion of participants |
| Placebo | Proportion of Participants With Improvement in the Participant's Overall Assessment Scale at Treatment Day 84 | 0.426 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196
Participants were asked if they had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of DUB during the past 12 weeks. The proportion of participants with such procedures is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196 | 0.024 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84
Participants were asked if they had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of DUB during the past 12 weeks. The proportion of participants with such procedures is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84 | 0.012 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196
Participants were asked if they had any medical treatment (eg, prescribed medication, other treatment) because of DUB during the past 12 weeks. The proportion of participants with such treatment is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196 | 0.047 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 196 | 0.043 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84
Participants were asked if they had any medical treatment (eg, prescribed medication, other treatment) because of DUB during the past 12 weeks. The proportion of participants with such treatment is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84 | 0.047 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Any Medical Treatment) at Treatment Day 84 | 0.062 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196
Participants were asked if there was any change in employment status in the last 12 weeks. The proportion of participants with a change is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196 | 0.129 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196 | 0.213 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84
Participants were asked if there was any change in her employment status in the last 12 weeks. The proportion of participants with a change is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84 | 0.221 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84 | 0.106 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196
Participants were asked how many days and hours were missed from work during the past 12 weeks because of problems associated with DUB, not including the time missed to participate in this study.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196 | 0.2 days | Standard Deviation 1.19 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196 | 0.4 days | Standard Deviation 1.51 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84
Participants were asked how many days and hours they missed from work during the past 12 weeks because of problems associated with DUB, not including the time missed to participate in this study.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84 | 0.4 day | Standard Deviation 1.84 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84 | 0.7 day | Standard Deviation 1.87 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196
Participants were asked to specify out-of-pocket expenses because of DUB during the past 12 weeks, including over-the-counter medication, co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with such expenses is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196 | 0.241 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 196 | 0.314 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84
Participants were asked to specify if they had out-of-pocket expenses because of DUB during the past 12 weeks, including over-the-counter medication (the name of the medication, the number of packages, and the cost per package), co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with such expenses is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84 | 0.323 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Out-of-pocket Expenses) at Treatment Day 84 | 0.407 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196
Participants were asked to rate on a scale of 0 to 10, how much DUB affected their productivity while working during the past 12 weeks, where 0 represented that DUB had no effect on work and 10 represented that DUB completely prevented her from working.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196 | 2.40 Scores on a scale | Standard Deviation 2.293 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196 | 4.03 Scores on a scale | Standard Deviation 3.123 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84
Participants were asked to rate on a scale of 0 to 10, how much their DUB affected productivity while working during the past 12 weeks, where 0 represented that DUB had no effect on work and 10 represented that DUB completely prevented her from working.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84 | 2.38 Scores on a scale | Standard Deviation 2.175 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84 | 3.07 Scores on a scale | Standard Deviation 2.088 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196
Participants were asked if they had received ambulatory services (eg, home help, child care) because of DUB during the past 12 weeks. The proportion of participants who had received such services is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196 | 0.012 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84
Participants were asked if they had received ambulatory services (eg, home help, child care) because of DUB during the past 12 weeks. The proportion of participants who received such services is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84 | 0.0 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196
Participants were asked to rate on a scale of 0 to 10 how much DUB affected their ability to do regular daily activities, other than work at a job, during the past 12 weeks where 0 represented that DUB had no effect on daily activities and 10 represented that DUB completely prevented her from doing her daily activities.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196 | 2.48 Scores on a scale | Standard Deviation 2.291 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196 | 4.10 Scores on a scale | Standard Deviation 2.903 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84
Participants were asked to rate on a scale of 0 to 10 how much DUB affected their ability to do their regular daily activities, other than work at a job, during the past 12 weeks where 0 represented that DUB had no effect on daily activities and 10 represented that DUB completely prevented her from doing daily activities.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84 | 2.81 Scores on a scale | Standard Deviation 2.551 |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84 | 3.91 Scores on a scale | Standard Deviation 2.466 |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196
Participants were asked if they had any unscheduled outpatient visits to a hospital because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196 | 0.012 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84
Participants were asked if they had any unscheduled outpatient visits to a hospital because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84 | 0.012 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196
Participants were asked if they had any unscheduled visits to a physician (non-hospital medical care) because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed.
Time frame: treatment day 196
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196 | 0.024 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 196 | 0.0 Proportion of participants |
Secondary
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84
Participants were asked if they had any unscheduled visits to a physician (non-hospital medical care) because of DUB during the past 12 weeks, not including visits that were due to participation in this study. The proportion of participants with such visits is displayed.
Time frame: treatment day 84
Population: ITT, excluding participants with missing data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84 | 0.012 Proportion of participants |
| Placebo | Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Visit to Physician) at Treatment Day 84 | 0.0 Proportion of participants |
Post Hoc
Change in Absolute Value From Baseline MBL to end-of Study MBL
The MBL for each cycle includes intermenstrual bleeding in addition to withdrawal bleeding. Baseline MBL was the mean MBL of measured MBL during three cycles in the run-in Phase. One cycle was defined as 28 days. For this analysis, the run-in Phase was defined by the days 1 to 84 (= 3 cycles each of 28 days). End of Study MBL was measured during Cycle 7 of the Treatment Phase (data imputation and Last Observation Carried Forward was applied).
Time frame: during a time period of 28 days under treatment
Population: Only participants with heavy menstrual bleeding were included in the analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Change in Absolute Value From Baseline MBL to end-of Study MBL | -114.60 mL | Standard Deviation 138.712 |
| Placebo | Change in Absolute Value From Baseline MBL to end-of Study MBL | -49.944 mL | Standard Deviation 117.038 |
Post Hoc
Proportion of Participants With Successful Treatment
End of Study menstrual blood loss (MBL) ≤ 80 mL and a decrease to a value of ≤ 50% of the Baseline MBL was considered as treatment success.
Time frame: during a time period of 28 days under treatment
Population: Only participants with heavy menstrual bleeding were included in the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Successful Treatment | End of study MBL <=80 mL | 0.568 Proportion of participants |
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Successful Treatment | Decrease MBL >=50% of baseline MBL | 0.568 Proportion of participants |
| Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Proportion of Participants With Successful Treatment | Successful treatment | 0.511 Proportion of participants |
| Placebo | Proportion of Participants With Successful Treatment | End of study MBL <=80 mL | 0.183 Proportion of participants |
| Placebo | Proportion of Participants With Successful Treatment | Decrease MBL >=50% of baseline MBL | 0.217 Proportion of participants |
| Placebo | Proportion of Participants With Successful Treatment | Successful treatment | 0.133 Proportion of participants |